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To the Editor, Malignant pleural effusions (MPE) affect an estimated 150,000 people per year in the US. (1) Average life expectancy following diagnosis is 4-6 months.(2) Management usually involves either insertion of an indwelling pleural catheter (IPC) or talc pleurodesis. Talc treatment typically requires a hospital stay of at least four days,(3) but IPCs allow ambulatory management and can be inserted as a day case. IPCs, however, induce pleurodesis less effectively, with success rates of approximately 45% (compared to 70% for talc) at a median of 52 days. (4) A new drug-eluting IPC has recently been developed, with the aim of enhancing effectiveness by the addition of an established pleurodesis agent, silver nitrate, as a slowrelease coating. The total dose delivered (100mg) is considerably lower than has historically been given during bolus administration. The SEAL-MPE study (NCT02227732, REC 13/WA/0379 and MHRA 2014/011/028/081/010) was a first-in-human trial designed to evaluate the basic safety profile of the novel silver nitrate-coated indwelling pleural catheter (SNCIPC) device in MPE. All patients documented informed consent and a safety data committee met at frequent intervals. Some of the results of this study have been previously reported in the form of an abstract. (5) The protocol and analysis plan were designed jointly by the investigators and the Sponsor. No deleterious increase in either blood or pleural fluid silver levels was identified, with peak median blood values noted on days 14 and 28 respectively. The peak median value for blood C-Reactive Protein (CRP) 103.5mg/L (56.0-142.0) was seen on day seven.
Given the short average life expectancy of those with MPE, it is vital to minimise the impact of effusions on quality of life. Some authors have attempted to use a normal IPC as a delivery method for a chemical agent, although this approach can mandate relatively frequent outpatient visits. (7) The SNCIPC tested in our study, however, is the first device which has attempted to truly be a complete solution. Indeed, although the general concept of drug-eluting devices is well-established, especially in coronary artery disease,(8) the SNCIPC is the first drug-eluting device designed for intrapleural use.
The relatively high number of recorded AEs was anticipated given the stringency of event recording and the palliative nature of the recruitment population. The SNCIPC nonetheless appeared to be well-tolerated, with 15/17 device-related AEs classed as mild. No cases of pneumonia were attributable to the device. One patient required the SNCIPC to be removed due to early pain, however pain is a common and expected side effect of both pleurodesis 
